Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.49 |
| ▸ | GABRP | O00591 | 6/20 | 0.49 |
| ▸ | GABRD | O14764 | 6/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.49 |
| ▸ | GABRE | P78334 | 6/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440953 | 0.98 | CYP1A2 (0.51) | CYP1A2KDM4EPOLBGABRA1GABRG2 | |
| SCHEMBL20267579 | 0.88 | ALDH1A1 (0.48) | CYP1A2KDM4EPOLBGABRA1GABRG2 | |
| SCHEMBL24573012 | 0.88 | JMJD6 (0.48) | CYP1A2KDM4EPOLBGABRA1GABRG2 | |
| SCHEMBL13545919 | 0.86 | POLB (0.40) | CYP1A2KDM4EPOLBGABRA1GABRG2 | |
| SCHEMBL23189019 | 0.85 | TSHR (0.50) | CYP1A2KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30234144 | 0.84 | CA12 (0.51) | CYP1A2KDM4EGABRA1GABRG2GABRB3 | |
| SCHEMBL29466587 | 0.84 | JMJD6 (0.57) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5778009 | 0.84 | CA12 (0.51) | CYP1A2KDM4EGABRA1GABRG2GABRB3 | |
| SCHEMBL159881 | 0.84 | CYP1A2 (0.51) | CYP1A2KDM4EPOLBGABRA1GABRG2 | |
| SCHEMBL930636 | 0.84 | JMJD6 (0.57) | CYP1A2GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684618-A | Argatroban middle Process for the preparation of intermediates | 山东新时代药业有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-11834436-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-116217466-A | Preparation method of argatroban intermediate 4-methyl-2-ethyl piperidine formate | 山东新时代药业有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | Hepagene Therapeutics (HK) Limited (HK) | 2019-08-15 | — | — | US | disclosed |
| US-20180072672-A1 | BIPYRIDYL COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-03-15 | — | — | US | disclosed |
| US-9908852-B2 | Bipyridyl compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-03-06 | — | — | US | disclosed |
| EP-2903078-B1 | METAL COMPLEX DYE, PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, DYE SOLUTION, AND DYE-ADSORBED ELECTRODE | FUJIFILM CORP (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-20170001960-A1 | BIPYRIDYL COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-01-05 | — | — | US | disclosed |
| EP-2903078-A1 | METAL COMPLEX DYE, PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, DYE SOLUTION, AND DYE-ADSORBED ELECTRODE | FUJIFILM Corporation (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-5849693-A | Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIb/IIIa | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| US-5773411-A | CARDIOVASCULAR DISORDERS AND BRAIN DISORDERS AND COAGULANTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| US-5691329-A | Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5563158-A | CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0672059-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994011398-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | NR1H4, FXR1, NR1H2 | CYP1A2 409/4885KDM4E 4596/4885POLB 4026/4885 |
| US-20170001960-A1 | BIPYRIDYL COMPOUND | CBR1, NR0B2, ERBB2 | CYP1A2 133/4885KDM4E 3386/4885POLB 1822/4885 |
| US-20180072672-A1 | BIPYRIDYL COMPOUND | CBR1, NR0B2, ERBB2 | CYP1A2 133/4885KDM4E 3386/4885POLB 1822/4885 |
| US-11834436-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | AIFM1, BAD, IRAK1 | CYP1A2 2564/4885KDM4E 1664/4885POLB 4815/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | CYP1A2 84/4885KDM4E 1902/4885POLB 3501/4885 |
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | AIFM1, BAD, IRAK1 | CYP1A2 2564/4885KDM4E 1664/4885POLB 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.